Wealthfront Inc. raised its stake in Danaher Co. (NYSE:DHR) by 16.0% in the 4th quarter, HoldingsChannel reports. The fund owned 18,987 shares of the conglomerate’s stock after buying an additional 2,613 shares during the quarter. Wealthfront Inc.’s holdings in Danaher were worth $1,762,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Roundview Capital LLC boosted its stake in shares of Danaher by 2.0% in the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares during the last quarter. Honeywell International Inc. boosted its stake in shares of Danaher by 113.4% in the 3rd quarter. Honeywell International Inc. now owns 640,100 shares of the conglomerate’s stock valued at $54,908,000 after purchasing an additional 340,100 shares during the last quarter. Veritable L.P. boosted its stake in shares of Danaher by 28.2% in the 2nd quarter. Veritable L.P. now owns 40,486 shares of the conglomerate’s stock valued at $3,417,000 after purchasing an additional 8,912 shares during the last quarter. Cibc World Markets Corp boosted its stake in shares of Danaher by 28.7% in the 2nd quarter. Cibc World Markets Corp now owns 300,808 shares of the conglomerate’s stock valued at $25,385,000 after purchasing an additional 67,075 shares during the last quarter. Finally, Progressive Investment Management Corp boosted its stake in shares of Danaher by 5.9% in the 4th quarter. Progressive Investment Management Corp now owns 37,108 shares of the conglomerate’s stock valued at $3,444,000 after purchasing an additional 2,074 shares during the last quarter. 77.05% of the stock is currently owned by institutional investors.
Danaher Co. (NYSE DHR) opened at $97.54 on Tuesday. Danaher Co. has a one year low of $78.97 and a one year high of $104.82. The firm has a market cap of $67,946.36, a P/E ratio of 27.63, a P/E/G ratio of 2.05 and a beta of 1.04. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43.
Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter last year, the firm earned $1.05 EPS. Danaher’s quarterly revenue was up 10.9% compared to the same quarter last year. analysts forecast that Danaher Co. will post 4.37 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were issued a dividend of $0.14 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.56 annualized dividend and a yield of 0.57%. Danaher’s dividend payout ratio (DPR) is currently 15.86%.
Several research analysts have recently issued reports on DHR shares. Stifel Nicolaus raised their target price on shares of Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Cowen reaffirmed a “buy” rating and issued a $110.00 target price on shares of Danaher in a research note on Tuesday, January 30th. UBS Group started coverage on shares of Danaher in a research note on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price on the stock. Robert W. Baird reaffirmed a “buy” rating on shares of Danaher in a research note on Friday, January 12th. Finally, Citigroup raised their target price on shares of Danaher to $107.00 and gave the company a “buy” rating in a research note on Friday, December 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $100.68.
In other Danaher news, CFO Daniel L. Comas sold 62,989 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the sale, the chief financial officer now directly owns 227,805 shares in the company, valued at approximately $23,226,997.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP William K. Daniel sold 131,066 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the sale, the executive vice president now owns 270,523 shares in the company, valued at $27,606,872.15. The disclosure for this sale can be found here. Insiders have sold a total of 237,043 shares of company stock worth $24,194,886 over the last 90 days. Corporate insiders own 12.20% of the company’s stock.
WARNING: This article was published by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thestockobserver.com/2018/02/20/wealthfront-inc-boosts-holdings-in-danaher-co-dhr.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.